Introduction
============

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated mortality worldwide ([@b1-ol-0-0-7946]), and the third most lethal cancer type in China, accounting for \>40% of global HCC-associated deaths ([@b2-ol-0-0-7946]). Despite recent advances in the diagnosis and treatment of HCC, it remains a highly lethal disease and the survival of most patients remains poor with no significant reduction in the mortality rate over the past decades. Even following radical resection of small HCC (tumor sizes \<3 cm), the 5-year postoperative recurrence and metastasis rate remains as high as 43.5% ([@b3-ol-0-0-7946]). The majority of HCC-associated deaths results from cancer metastasis. In addition, the heterogeneities of HCC make the problem even worse in clinical oncology ([@b4-ol-0-0-7946]). It has generally been recognized that cancer invasion, including HCC invasion, is not merely a local problem involving cells in the local tumor microenvironment, but the result of the activity of numerous oncogenic somatic immune cells cancer cells throughout the body ([@b5-ol-0-0-7946]). With this regard, a fundamental importance lies in changes in the tumor microenvironment ([@b5-ol-0-0-7946]). The dynamic evolution of cancer cells within and at the borders of the tumor microenvironment is crucial in every aspect of tumor progression ([@b5-ol-0-0-7946]). The role of the tumor microenvironment, including stromal cells and the extracellular matrix (ECM), varies from ECM remodeling to determining the polarity of tissue by linearization of interstitial collagens at tumor invasion front ([@b6-ol-0-0-7946]), to the recruitment of immune cells as it has been reported that collagen degradation products serve as chemotactic stimuli for monocytes ([@b7-ol-0-0-7946]), for the acquisition of features defined as 'cancer hallmarks' to generate a physiologically dysfunctional microenvironment. Therefore, rich information hidden in the tumor microenvironment should be systematically investigated to gain a complete understanding of cancer invasion-associated biology.

The ECM has been traditionally regarded as a physical scaffold that holds cells and tissues together, and its remodeling is a common feature of diverse pathological processes, including tissue fibrosis and cancer ([@b8-ol-0-0-7946],[@b9-ol-0-0-7946]). The correlation between tissue fibrosis and cancer has attracted increasing attention from clinicians ([@b10-ol-0-0-7946]). During cancer invasion, ECM scaffolds undergo considerable structural remodeling, characterized by increased deposition of fibronectin, proteoglycans and collagens, and enhanced matrix cross-linking ([@b11-ol-0-0-7946]), accompanied with tumor angiogenesis, as well as recruitment and conversion of immune cells ([@b12-ol-0-0-7946]). The balance of ECM degradation and re-deposition is disrupted, which actively induces epithelial-mesenchymal transition (EMT) of cancer cells ([@b13-ol-0-0-7946],[@b14-ol-0-0-7946]). Consequently, the cancer cells are able to migrate from the ECM and develop metastases through stromal cells and immune responses ([@b15-ol-0-0-7946]), by participating in signaling transduction between the ECM and cancer cells ([@b16-ol-0-0-7946]), in which the collagen degradation products recruit monocytes, and immune cells aid collagen reorganization to improve cancer cell penetration ([@b17-ol-0-0-7946]). In addition, angiogenesis, the formation of tumor neo-vasculature, is essential for any malignant tumor type, including HCC, as tumors must recruit vessels to secure oxygen and nutrient supply, and to remove waste products ([@b18-ol-0-0-7946],[@b19-ol-0-0-7946]). Macrophages also have important roles in cancer cell invasion and metastasis by regulating the immune response of the body to cancer cells and secrete various cytokines ([@b20-ol-0-0-7946]). A study by Ruffell *et al* ([@b21-ol-0-0-7946]) demonstrated that macrophages promote cancer invasion in Hodgkin\'s lymphoma, while other studies indicated that macrophages inhibit colon cancer invasion ([@b22-ol-0-0-7946]) or that they have no influence on the prognosis of cancer patients ([@b23-ol-0-0-7946]).

The present study aimed to assess the density of macrophages, tumor neo-vessels and the expression of α-SMA in tumor stroma in order to investigate the heterogeneity of the tumor microenvironment in depth, in an attempt to provide a guide for improving the individual treatment strategy for patients with HCC.

Materials and methods
=====================

### Patients and specimens

A total of 3 separate HCC tissue sections (4 µm) from 101 patients with HCC were collected from Zhejiang Cancer Hospital (Hangzhou, China) between January 2012 and December 2014. The study protocol was approved by the Institutional Ethics Committee of Zhejiang Cancer Hospital (Hangzhou, China) and the patients provided written informed consent regarding the use of their tissues. Major clinicopathological features of these patients are listed in [Table I](#tI-ol-0-0-7946){ref-type="table"}. All of the cases underwent curative radical surgery without neo-adjuvant radiotherapy or chemotherapy. Tumor staging was based on the tumor-nodes-metastasis (TNM) classification system of the American Joint Committee on Cancer staging criteria (version 7) ([@b24-ol-0-0-7946]). The median follow-up was 41 months. Disease-free survival (DFS) was defined as the interval from the date of surgery to recurrence, and if no recurrence was identified, patients were censored on the date of death or the last follow-up. Evidence of disease recurrence was based on the following criteria: The concentration of AFP (\>200 ng/ml), local recurrence identified on ultrasonography, computed tomography (CT) or magnetic resonance imaging; peritoneal dissemination on ultrasonography or CT scan with positive peritoneal cytology; lung metastasis on chest radiography; and bone metastasis on radiography or bone scan on emission computed tomography.

### Immunohistochemical staining

Immunohistochemical staining of macrophages marked by CD68, tumor neo-vessels marked by CD105 and α-SMA were performed using the streptavidin-biotin peroxidase complex method. In brief, tissue slides were first deparaffinized in xylene, ethanol and water, and then the slides were treated with 0.01 M citrate buffer (pH 6.0) and heated in a microwave oven at 98°C for 10 min. For staining, endogenous peroxidase activity was blocked by immersing samples in 3% H~2~O~2~ in methanol for 10 min at 37°C to prevent any nonspecific binding. After blocking with 2% bovine serum albumin (Shanghai Ruji Biotechnology, Shanghai, China), the slides were incubated with primary antibodies to CD68 (cat. no. MA1-38069; dilution, 1/300; Affinity BioReagents, Golden, CO, USA), CD105 (ab-169545; dilution, 1/300; Abcam, Cambridge, MA, USA) and α-SMA (ab-5694; dilution, 1/300; Abcam) for 90 min at 37°C, and then incubated with the corresponding secondary antibody for 15 min at 37°C, and finally incubated with peroxidase-labeled streptavidin (cat. no., 091014395C; dilution, 1:250; Maixin Biotechnology, Fuzhou, China) for 15 min. The reaction products were visualized with diaminobenzidine (DAKO, Glostrup, Denmark). All slides were counterstained with hematoxylin for 2 min at room temperature. As a negative control, the primary antibody was replaced with Tris-buffered saline on sections.

### Quantification of immunohistochemical staining

The slides were examined under an Olympus BX51 microscope equipped with an Olympus DP72 camera (Olympus Optical Co., Ltd., Tokyo, Japan) and the CRi Nuance multispectral imaging system (Cambridge Research & Instrumentation, Inc., Woburn, MA, USA). Positive staining was indicated by brownish granules. A spectral cube for each image, which contains the complete spectral information at 10 nm wavelength intervals from 420 to 720 nm, was collected using the CRi Nuance multispectral imaging system. For each cube identical settings were used to avoid selection bias. Positive signal unmixing was performed using the software package within the Nuance system as previously described ([@b25-ol-0-0-7946]). Then, after obtaining the images of signal unmixing, the infiltrating macrophages marked by CD68 and tumor neo-vessels marked by CD105 were counted in five high-power fields selected at the tumor site, and the mean cells counts were documented. The thickness of infiltrating stroma marked by α-SMA was measured to evaluate the depth between tumor nests. For determining the density of infiltrating macrophages, neo-vessels density and thickness of the stroma, the cutoff value to classify subgroups was 270, 215 and 238.6 µm respectively ([@b26-ol-0-0-7946]), according to the mean value.

### Statistical analysis

Statistical analyses were performed with SPSS software version 21.0 (IBM Corp., Armonk, NY, USA). For categorical data, χ^2^ test was performed. The Kaplan-Meier method was used to estimate survival curves for DFS and the log-rank test was used to assess the difference in survival and recurrence rates between subgroups. The Cox regression model was used to perform univariate and multivariate analyses. Logistic regression was used to assess the influence of binary factors. A two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Major clinicopathological features of 101 HCC cases

Among the 101 HCC cases included in this study, 90 (89.1%) were males and 11 (10.9%) were females, ranging in age from 19 to 75 years (median age, 51 years). The major demographic and clinicopathological characteristics are presented in [Table I](#tI-ol-0-0-7946){ref-type="table"}. Immunohistochemical analysis was performed on all HCC tissue sections and the corresponding images of signal unmixing for tumor neo-vessels and macrophages were obtained with the CRi Nuance multispectral imaging system ([Fig. 1](#f1-ol-0-0-7946){ref-type="fig"}).

### Association between tumor neo-vessels, macrophages, α-SMA and clinicopathological features

CD105, CD68 and α-SMA staining was mainly located in the cytoplasm or on the cell membrane. Tumor neo-vessels (stained by CD105) and macrophages (stained by CD68) were distributed in tumor nests as well as in tumor stroma. α-SMA staining was mainly located in the tumor stroma. The majority of the cancer cells were negative for α-SMA staining, although sporadic positive staining on these cells was also observed. However, all above components, including tumor neo-vessels, macrophages and α-SMA, were heterogeneously expressed in the tumor microenvironment ([Fig. 2](#f2-ol-0-0-7946){ref-type="fig"}). In certain cases, only few tumor neo-vessels and macrophages were present compared with other cases with a rich distribution in tumor tissues. The amount of α-SMA distributed in the stroma was also different among the patients.

The quantitative data of tumor neo-vessels, macrophage density and stromal thickness are presented in [Table II](#tII-ol-0-0-7946){ref-type="table"}. For infiltrating macrophage density, neo-vessel density and thickness of the stroma, the cutoff value to classify subgroups was 270, 215 and 238.6 µm respectively. In the high and low tumor neo-vessel subgroups, 24 (52.2%) and 16 (36.4%) of cases, respectively, had a high macrophage density. In the high and low α-SMA subgroups, 29 (58.0%) and 19 (40.4%) of cases, respectively, had a high tumor neo-vessel density, and 23 (48.9%) and 17 (39.5%) of cases, respectively, had a high macrophage density. Of note, the tumor neo-vessel, macrophage and α-SMA densities were not significantly correlated with any of the clinicopathological features, as summarized in [Table II](#tII-ol-0-0-7946){ref-type="table"}, which indicated that these key components of the tumor microenvironment were independent from clinical features including tumor size, tumor number, TNM stage and venous infiltration.

### Survival analysis

For the 101 HCC cases, the median DFS was 5.0 months (range, 22 days-54.0 months). As expected, several clinical factors were associated with the DFS of HCC patients, including tumor size, venous infiltration and tumor recurrence (P\<0.05 for all). Furthermore, tumor macrophage and α-SMA densities were negatively associated with DFS (P=0.022 and P\<0.001, respectively). In addition, the combined features based on the above three key components in the tumor microenvironment were explored to reveal the association between key stromal factors with HCC prognosis. According to the expression levels of the three key stromal components, patients were divided into three subgroups according to the density of tumor neo-vessels, macrophages and α-SMA: Group I, all three components were expressed at a low level; group II, 1 or 2 components were expressed at a high level; group III, three components were expressed at a high level. Combined analysis indicated that patients in group III had a worse DFS than those in groups I and II (P=0.001; [Fig. 3D](#f3-ol-0-0-7946){ref-type="fig"}).

### Multivariate analysis

In univariate analysis, traditional clinicopathological features (including tumor size, venous infiltration and recurrence status), macrophage density and α-SMA were associated with DFS. In addition, analysis of the combined key stromal components of tumor neo-vessels, macrophages and α-SMA indicated that the mortality risk in combined group III was significantly increased (P=0.001).

As presented in [Table III](#tIII-ol-0-0-7946){ref-type="table"}, in the multivariate analysis Model 1, all factors were integrated into a multivariate Cox proportional hazards analysis. Liver cirrhosis status, tumor recurrence status, macrophage density and α-SMA density were independent prognostic factors for DFS (P\<0.05 for all). In Model 2, factors exhibiting significance according to a univariate analysis were integrated into a multivariate Cox proportional hazards analysis in order to avoid multicollinearity among those variables. Tumor recurrence status, macrophage density and α-SMA density were independent prognostic factors for DFS (P\<0.05 for all).

Discussion
==========

It has generally been recognized that cancer invasion, including HCC invasion, is not merely a local problem, but a multifactor and multistep continuum, with a variety of molecular dysfunction and cell signaling dysregulation. The genetic or epigenetic changes of cancer cells are the 'initial factors' of carcinogenesis, and the responses of stromal cells in the tumor microenvironment may 'promote' or 'regulate' cancer invasion and metastasis, which ultimately results in an altered tumor microenvironment favoring cancer invasion and progression ([@b27-ol-0-0-7946]). The temporal-spatial evolution of the microenvironment and the interplay between cancer cells and their microenvironment are critical in every aspect of tumor development, including cancer cell dormancy, proliferation, invasion and migration ([@b5-ol-0-0-7946]). Currently, the importance of the tumor microenvironment has been increasingly appreciated, from the physical structures to chemical components, particularly the role of macrophages and tumor neo-vessels and the structure of tumor stroma. Inflammation and tumor angiogenesis are two indispensable factors for cancer invasion ([@b28-ol-0-0-7946]). The tumor mass relies on blood vessels to gain nutrients and dispose of waste in order to keep growing ([@b29-ol-0-0-7946]). Typical features of tumor neo-vessels, including irregular shape, disordered structure, high permeability and immaturity contribute to the spreading of tumor cells to distant organs ([@b30-ol-0-0-7946]). However, the present study demonstrated that tumor neo-vessels are not significantly associated with the prognosis of HCC patients. It is therefore suggested that other key components in the tumor microenvironment, e.g. macrophages, have presumed the significant role of tumor neo-vessels in the process of cancer invasion and metastasis. Tumor-associated macrophages have crucial roles in tumor angiogenesis, including prompting the production of vascular endothelial cells, boosting vessel sprouting and accelerating cancer invasion and metastasis ([@b31-ol-0-0-7946]). The results of the present study indicated that macrophages indeed have a profound impact on HCC progression and are independent prognostic factors for HCC. In addition, macrophages synthesize other stromal matrix components, including hyaluronic acid, matrix metalloproteinase and fibroblast-activated proteins, all of which may contribute to cancer invasion and metastasis ([@b32-ol-0-0-7946]). In the present study, it was also confirmed that the density of tumor stroma marked by α-SMA was highly associated with HCC prognosis and was an independent prognostic factor for HCC patients. Numerous other studies have reported that fibroblasts promote lymph node metastasis ([@b33-ol-0-0-7946],[@b34-ol-0-0-7946]). It has been suggested that the biological characteristics of fibroblasts in normal tissues are exceptionally distinguished from those in cancer tissues ([@b35-ol-0-0-7946]). The majority of fibroblasts are located at the invasion frontier, the interface between tumor mass and surrounding stroma, or near the tumor neo-vessels in the tumor microenvironment, regulating the growth and invasion of cancer cells by synthetizing and remodeling ECM, participating in the process of tumor angiogenesis and downregulating the of the anti-tumor immune response ([@b36-ol-0-0-7946]). In the present study, increased of fibroblast density indicated thicker stroma and worse prognosis. It was previously reported that the stiffness of the stroma is closely associated with the risk of carcinogenesis ([@b37-ol-0-0-7946]) and fibrosis is relevant to poor prognosis of cancer patients ([@b38-ol-0-0-7946]). Tumors are normally characterized as lumps of great toughness, which prompted oncologists to investigate the concept that tumor progression may be eased by decreasing the toughness of tissues ([@b39-ol-0-0-7946]). Others have confirmed that only a slight change in the toughness of stroma or in mechanical signals affects the biological behavior of cells ([@b40-ol-0-0-7946]). Thus, the significance of research into the tumor microenvironment is particularly prominent.

In conclusion, key components in the tumor microenvironment may interact with cancer cells, and together accelerate the cancer invasion and metastasis. The present study implied that tumor-associated macrophages and the expression of α-SMA are intimately linked with the prognosis of HCC patients. However, further research using larger amounts of samples is still required to confirm and interpret relevant mechanisms in more depth.
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![Immunohistological analysis of hepatocellular carcinoma tissue sections. Representative immunohistochemical images of (A and B) tumor neo-vessels stained for CD105 and of (C and D) macrophages stained for CD68. B and D display the corresponding images following signal unmixing with the CRi Nuance multispectral imaging system (scale bar, 50 µm).](ol-15-04-4805-g00){#f1-ol-0-0-7946}

![Heterogeneous density of stromal components in the hepatocellular carcinoma microenvironment. (A and B) Tumor neo-vessels in HCC with (A) scattered and discrete distribution and (B) high density. (C and D) Macrophages in HCC tissue with (C) low and (D) high density. (E and F) Fibroblasts in HCC tissues with (E) low and (F) high density as determined by immunohistochemical detection of α-smooth muscle actin (scale bar, 50 µm).](ol-15-04-4805-g01){#f2-ol-0-0-7946}

![Cumulative DFS of patients with HCC. (A) Tumor neo-vessels were not associated with DFS of patients with HCC. (B and C) Patients in the high-density (B) macrophage and (C) α-SMA expression groups had a higher risk of death. (D) Combined features accurately indicated DFS of patients with HCC. HCC, hepatocellular carcinoma; DFS, disease-free survival; CI, confidence interval; SMA, smooth muscle actin. Group I, all three components were expressed at a low level; group II, 1 or 2 components were expressed at a high level; group III, 3 components were expressed at a high level.](ol-15-04-4805-g02){#f3-ol-0-0-7946}

###### 

Major demographic and clinicopathological characteristics of hepatocellular carcinoma cases (n=101).

  Item                         Value
  ---------------------------- ---------------
  Age (years)                  51 (19--75)
  Sex                          
    Male                       90 (89.1)
    Female                     11 (10.9)
  Tumor size (cm)              
    ≤5                         26 (25.7)
    \>5                        75 (74.3)
  Tumor number                 
    Single                     86 (85.1)
    Multiple                   15 (14.9)
  AFP (ng/ml)                  
    ≤200                       54 (53.5)
    \>200                      47 (46.5)
  Liver cirrhosis              
    No                         58 (57.4)
    Yes                        43 (42.6)
  Venous infiltration          
    No                         53 (52.5)
    Yes                        48 (47.5)
  TNM stage                    
    Early (Stage I, II)        47 (46.5)
    Advanced (Stage III, IV)   54 (53.5)
  Tumor recurrence             
    No                         37 (36.6)
    Yes                        64 (63.4)
  Distant metastasis           
    No                         46 (45.5)
    Yes                        55 (54.5)
  DFS (Median, range)          5.0 (0--54.0)

Values are expressed as median (range) or n (%). TNM, tumor-nodes-metastasis; AFP, α-fetoprotein; DFS, disease-free survival.

###### 

Association between the density of tumor neo-vessels, macrophages and α-SMA expression, and clinicopathological features.

                        Tumor neo-vessel density   Macrophage density   α-SMA expression                                                                                   
  --------------------- -------------------------- -------------------- ------------------ ------- ----------- ----------- ------- ------- ----------- ----------- ------- -------
  Age (years)                                                           0.511              0.634                           1.000   0.102                           4.408   0.060
    \<60                39 (52.0)                  36 (48.0)                                       38 (55.1)   31 (44.9)                   32 (42.1)   44 (57.9)           
    ≥60                 10 (43.5)                  13 (56.5)                                       13 (59.1)   9 (40.9)                    16 (66.7)   8 (33.3)            
  Gender                                                                0.102              0.749                           0.071   0.789                           0.670   0.529
    Male                44 (50.6)                  43 (49.4)                                       45 (55.6)   36 (44.4)                   44 (49.4)   45 (50.6)           
    Female              5 (45.5)                   6 (54.5)                                        6 (60.0)    40 (40.0)                   4 (36.4)    7 (63.6)            
  Tumor size (cm)                                                       2.631              0.164                           0.679   0.467                           1.322   0.265
    ≤5                  9 (36.0)                   16 (64.0)                                       14 (63.6)   8 (36.4)                    15 (57.7)   11 (42.3)           
    \>5                 40 (54.8)                  33 (45.2)                                       37 (53.6)   32 (46.4)                   33 (44.6)   41 (55.4)           
  Tumor number                                                          1.968              0.261                           0.633   0.539                           0.545   0.568
    Single              39 (47.0)                  44 (53.0)                                       43 (54.4)   36 (45.6)                   40 (46.5)   46 (53.5)           
    Multiple            10 (66.7)                  5 (33.3)                                        8 (66.7)    4 (33.3)                    8 (57.1)    6 (42.9)            
  AFP (ng/ml)                                                           1.027              0.418                           0.038   0.845                           3.344   0.075
    ≤200                24 (45.3)                  29 (54.7)                                       27 (55.1)   22 (44.9)                   30 (56.6)   23 (43.4)           
    \>200               25 (55.6)                  20 (44.4)                                       24 (57.1)   18 (42.9)                   18 (38.3)   29 (61.7)           
  Liver cirrhosis                                                       0.377              0.682                           0.091   0.832                           2.425   0.156
    No                  27 (47.4)                  30 (52.6)                                       29 (54.7)   24 (45.3)                   24 (41.4)   34 (58.6)           
    Yes                 22 (53.7)                  19 (46.3)                                       22 (57.9)   16 (42.1)                   24 (57.1)   18 (42.9)           
  Venous infiltration                                                   0.368              0.686                           2.724   0.139                           0.334   0.689
    No                  24 (47.1)                  27 (52.9)                                       23 (47.9)   25 (52.1)                   24 (45.3)   29 (54.7)           
    Yes                 25 (53.2)                  22 (46.8)                                       28 (65.1)   15 (34.9)                   24 (51.1)   23 (48.9)           
  TNM stage                                                             1.027              0.418                           2.247   0.145                           1.054   0.324
    Early               20 (44.4)                  25 (55.6)                                       20 (47.6)   22 (52.4)                   20 (42.6)   27 (57.4)           
    Advanced            29 (54.7)                  24 (45.3)                                       31 (63.3)   18 (36.7)                   28 (52.8)   25 (47.2)           
  Tumor recurrence                                                      0.180              0.832                           0.437   0.661                           0.109   0.837
    No                  18 (52.9)                  16 (47.1)                                       20 (60.6)   13 (39.4)                   17 (45.9)   20 (54.1)           
    Yes                 31 (48.4)                  33 (51.6)                                       31 (53.4)   27 (46.6)                   31 (49.2)   32 (50.8)           
  Distant metastasis                                                    0.164              0.840                           2.247   0.145                           0.511   0.113
    No                  22 (47.8)                  24 (52.2)                                       20 (47.6)   22 (52.4)                   18 (39.1)   28 (60.9)           
    Yes                 27 (51.9)                  25 (48.1)                                       31 (63.3)   18 (36.7)                   30 (55.6)   24 (44.4)           

Values are expressed as n (%). TNM, tumor-nodes-metastasis; AFP, alpha-fetoprotein.

###### 

Multivariate analyses of factors associated with DFS.

                                                                                Univariate analysis   Multivariate analysis                                       
  ----------------------------------------------------------------------------- --------------------- ----------------------- ---------------- --------- -------- ---------------
  Age (\<60 vs. ≥60 years)                                                      0.284                 1.014                   0.988--1.040                        
  Sex (female vs. male)                                                         0.381                 0.588                   0.180--1.926                        
  Tumor size (≤5 vs. \>5)                                                       0.979                 0.989                   0.442--2.216     0.181     1.552    0.815--2.956
  Tumor number (single vs. multiple)                                            0.402                 0.558                   0.142--2.188                        
  AFP (≤200 vs. \>200)                                                          0.088                 1.742                   0.921--3.293                        
  Liver cirrhosis (no vs. yes)                                                  0.020                 0.514                   0.294--0.899                        
  Venous infiltration (no vs. yes)                                              0.141                 0.277                   0.050--1.530     0.696     1.114    0.649--1.910
  TNM stage (early vs. advanced)^[a](#tfn3-ol-0-0-7946){ref-type="table-fn"}^   0.098                 4.955                   0.745--32.937                       
  Tumor recurrence (no vs. yes)                                                 \<0.001               28.416                  7.979--101.205   \<0.001   17.035   5.644--51.415
  Distant metastasis (no vs. yes)                                               0.411                 0.755                   0.386--1.476                        
  Tumor neo-vessel density (low vs. high)                                       0.794                 1.000                   0.997--1.002                        
  Macrophage density (low vs. high)                                             0.008                 1.004                   1.001--1.007     0.025     1.870    1.082--3.233
  α-SMA expression (low vs. high)                                               0.005                 1.004                   1.001--1.007                        

Early, TNM stage I/II; advanced, TNM stage III/IV. DFS, disease-free survival; SMA, smooth muscle actin; TNM, tumor-nodes-metastasis; HR, hazard ratio; CI, confidence interval.
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